CMPX
What one share of Compass Therapeutics holds
Biological Products, (No Diagnostic Substances)
We are a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. Our scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth.
Compass Therapeutics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$0.40 |
|---|---|
| Capex (buildings and equipment) | $0.00 |
| Free cash flow | −$0.31 |
| Cash and investments | $1.00 |
| Book value | $0.92 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2019 | — | −$0.01 | — | −$0.01 | — | −$19.06 |
| 2019 | — | −$5.19 | $0.07 | −$4.81 | — | $1.60 |
| 2020 | — | −$0.01 | — | −$0.01 | — | −$24.95 |
| 2020 | — | −$0.96 | $0.00 | −$0.87 | — | $0.78 |
| 2021 | — | −$1.31 | $0.02 | −$0.34 | — | $1.39 |
| 2022 | — | −$0.37 | $0.00 | −$0.33 | — | $1.44 |
| 2023 | $0.00 | −$0.33 | $0.00 | −$0.32 | — | $1.16 |
| 2024 | $0.01 | −$0.36 | $0.00 | −$0.33 | — | $0.91 |
| 2025 | $0.00 | −$0.42 | $0.00 | −$0.31 | — | $1.10 |